Modular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System

Reuters
09/15
Modular Medical Inc. Receives IRB Approval for Feasibility Study of Next-Gen Pivot Insulin Delivery System

Modular Medical Inc., a leader in innovative insulin delivery technology, announced that it has received Institutional Review Board (IRB) approval to conduct an in-house feasibility study of its next-generation Pivot insulin delivery system. The study will evaluate the usability and extended wear of the tubeless patch pump using sterile saline on adult participants over a period of up to 90 days. This approval is a crucial step toward refining the Pivot pump before its anticipated 510(k) submission to the FDA in October 2025. The study aims to identify challenges in prolonged wear, gather participant feedback, and support regulatory pathways to potentially unlock new markets. The Pivot pump is not yet cleared for sale by the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modular Medical Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073041) on September 15, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10